Literature DB >> 33592653

Suspected Acute Pulmonary Embolism: Gestalt, Scoring Systems, and Artificial Intelligence.

Delphine Douillet1, Pierre-Marie Roy1, Andrea Penaloza2.   

Abstract

Pulmonary embolism (PE) remains a diagnostic challenge in 2021. As the pathology is potentially fatal and signs and symptoms are nonspecific, further investigations are classically required. Based on the Bayesian approach, clinical probability became the keystone of the diagnostic strategy to rule out PE in the case of a negative testing. Several clinical probability assessment methods are validated: gestalt, the Wells score, or the revised Geneva score. While the debate persists as to the best way to assess clinical probability, its assessment allows for the good interpretation of the investigation results and therefore directs the correct diagnostic strategy. The wide availability of computed tomography pulmonary angiography (CTPA) resulted in a major increase in investigations with a moderate increase in diagnosis, without any notable improvement in patient outcomes. This leads to a new challenge for PE diagnosis which is the limitation of the number of testing for suspected PE. We review different strategies recently developed to achieve this goal. The last challenge concerns the implementation in clinical practice. Two approaches are developed: simplification of the strategies versus the use of digital support tools allowing more sophisticated strategies. Artificial intelligence with machine-learning algorithms will probably be a future tool to guide the physician in this complex approach concerning acute PE suspicion. Thieme. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33592653     DOI: 10.1055/s-0041-1723936

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  1 in total

1.  Predictive Value of MPV and Plasma NT-ProBNP Combined with the Simplified Geneva Scale for the Prognosis of Acute Pulmonary Embolism.

Authors:  Jing Wang; Lu Wang; Ling Jin; Xiaolei Rong; Xueshuang Tang; Haina Guo; Xiaochuan Liu; Lei Shi; Guilu Tao
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-19       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.